Whalesbook
Lasa Supergenerics ne shareholders ko ek important update diya hai! Unki board meeting finally May 29, 2026 ko set ho gayi hai. Is meeting ka main agenda FY26 aur Q4FY26 ke liye audited financial results ko approve karna hai.
FY25 Ka Performance Kitna Accha Tha? (Benchmark Check)
Ek idea dene ke liye, pichhle saal FY25 mein (jo March 31, 2025 ko khatam hua), Lasa Supergenerics ka consolidated revenue ₹223.71 crore tha, aur profit after tax ₹4.79 crore kamaya tha. Usi saal ke Q4 mein, consolidated revenue ₹56.39 crore aur profit ₹1.13 crore tha. Ab sab ki nazar FY26 ke numbers par hai.
Trading Window Band Kyun Hogi? (Market Rules)
Company ne yeh bhi bataya hai ki board meeting ke baad, unki trading window band kar di jayegi. Yeh window results publicly announce hone ke 48 hours baad hi open hogi. Yeh ek standard practice hai insider trading ko rokne ke liye.
Company Ka Business Aur Turnaround Efforts
Lasa Supergenerics primarily Active Pharmaceutical Ingredients (APIs) banati hai, jo veterinary aur human health sectors mein use hote hain. Pichle kuch saalon se company apni financial performance ko improve karne aur growth ko phir se lane ki koshish kar rahi hai.
Investors Ko Kya Dekhna Hai?
FY26 ke final results investors ko company ki profitability aur overall financial health ka clear picture denge. Management ki commentary aur future outlook bhi important hogi. Iske saath hi, API sector mein competitors jaise Divi's Laboratories, Laurus Labs, Aarti Drugs, aur Solara Active Pharma Sciences ke beech company kahan khadi hai, yeh bhi dekha jayega.